版本:
中国

BRIEF-Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent

April 25 Catabasis Pharmaceuticals Inc

* Catabasis Pharmaceuticals announces favorable results for functional assessments in the MoveDMD trial for edasalonexent in duchenne muscular dystrophy at the American Academy of Neurology 69th annual meeting

* Catabasis Pharmaceuticals Inc - Part C interim results to be announced in Q3 2017 for MoveDMD trial for edasalonexent

* Catabasis Pharmaceuticals - prespecified analysis of Part B data from MoveDMD trial shows improvement in rates of change across 5 functional assessments

* Catabasis Pharmaceuticals Inc - consistent with Part A, there were no safety signals and edasalonexent was well tolerated in Part B of trial

* Catabasis Pharmaceuticals - there were no treatment-related serious adverse events, no drug discontinuations and no dose reductions in Part B of trial Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐